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In this issue of the BJD, Farah et al. reported a case of spitzoid
melanoma with morphological characteristics of an ALK-
rearranged spitzoid neoplasm and copy number gain, rather
than rearrangement, of the ALK gene.1 This case is interesting
in that it demonstrates a novel mechanism by which ALK
may be activated in spitzoid melanoma. It also expands the
spectrum of ALK alterations associated with the plexiform
spitzoid phenotype, namely intersecting fascicles of amelan-
otic fusiform melanocytes. The authors additionally provided
a concise overview of the different types of ALK alterations
that have been identified in spitzoid neoplasms. In this mod-
ern era, where molecular data continue to accumulate at a fast
pace, this article serves as a timely and up-to-date guide to this
subject.
It is now known that approximately 50% of spitzoid lesions
harbour kinase fusions of ALK, BRAF, ROS1, RET, NTRK1 or MET.2
Such fusions result in constitutive activation of oncogenic sig-
nalling pathways and ultimately proliferation of melanocytes.
Of these kinases, BRAF is the most extensively studied in the
realm of melanocytic lesions, and myriad activating alterations
(point mutations, amplifications and gene rearrangements) have
been identified.3 Our insight into ALK alterations in melanocytic
lesions is following a similar path, where various activation
mechanisms such as copy number gain and alternative tran-
scription initiation are being increasingly recognized after the
initial description of gene rearrangement.1,4
Besides kinases, a number of other genes (HRAS, CDKN2A,
BAP1 and TERT) are implicated in the pathogenesis of spitzoid
neoplasms.5 Many of these genetic changes are associated with
a unique histomorphology and/or immunophenotype which
may be used as surrogates of these changes, thereby streamlin-
ing the diagnostic process. The case illustrated by Farah et al.
is an excellent example in which a plexiform spitzoid mor-
phology raised consideration of an ALK-rearranged spitzoid
melanoma, and prompted ALK immunohistochemistry and
fluorescence in situ hybridization, which led to the finding of
ALK copy number gain.1 Other well-known genotype–pheno-
type correlations include BAP1-inactivated atypical Spitz nae-
vus/tumour and HRAS mutation/amplification in desmoplastic
Spitz naevus, both of which are typically associated with an
indolent behaviour, in contrast to those with homozygous
CDKN2A deletion or TERT promoter mutation.5
As our understanding of the molecular underpinnings of
spitzoid neoplasms continues to evolve, additional genes
of interest may emerge, possibly implicating new mechanisms
of neoplastic transformation. Refining the different modes of
genetic alteration will likely prove important in diagnostic
classification, as well as predicting prognosis and response to
targeted therapy.
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Tsai et al. performed an extensive meta-analysis of observa-
tional studies investigating serum homocysteine, folate and
vitamin B12 levels in patients with psoriasis and in a control
population.1 Among 990 initially identified, they selected 24
high-quality studies that were considered eligible to be
included. The major finding of the study was that psoriasis is
significantly associated with hyperhomocysteinaemia and
folate deficiency but not with vitamin B12 deficiency. In par-
ticular, the odds ratio of hyperhomocysteinaemia in patients
with psoriasis was 348 (95% confidence interval 208–583),
© 2019 British Association of DermatologistsBritish Journal of Dermatology (2019) 180, pp253–263
262 Commentaries
